Table 3

Table 3. Genetic Vaccines for Experimental Mouse Tumors: Self Tumor Antigens

Antigen	Tumor	Immunization schedule	Adjuvant	Antitumor activity	Reference
Neu	spontaneous mammary tumor	DNA, i.m., 4 weekly inoculations	IL-2-encoding plasmid	partial protection from challenge	[Chen et al., 1998]
P1A	mastocytoma	DNA, i.m., 3 inoculations every 10 days	none	partial protection from challenge	[Rosato et al., 1997]
Idyotype/ GM-CSF fusion protein	B-cell lymphoma	DNA, i.m., 3 inoculations every 3 weeks	none	partial protection from challenge	[Syrengelas et al., 1996]
Mouse TRP-2	melanoma	DNA, 3 gene gun bombardments, every 2 weeks	IL-12-encoding plasmid	partial protection from challenge	[Tuting et al., 1999]
Human TRP-1	melanoma	DNA, 5 gene gun bombardments, weekly	none	reduction of pulmonary metastases upon challenge; vitiligo	[Weber et al., 1998]
Human TRP-2	melanoma	DNA, 1-4 gene gun bombardments	GM-CSF (in therapy setting)	reduction of pulmonary metastasaes (prevention and therapy); vitiligo	[Bowne et al., 1999a]
Mouse TRP-2	melanoma	DNA, i.m. single injection	cardio-toxin	protection from challenge; no vitiligo	[Bronte et al., 2000b]
P1A	mastocytoma	Semiliki Forest virus particles, 2 i.v. injections	none	protection from challenge	[Colmenero et al., 1999]
Mouse TRP-2 and gp100	melanoma	S. thyphimurium encoding an ubiquitin-miniepitope complex, given by oral gavage	none	partial protection from challenge	[Xiang et al., 2000]
Mouse TRP-1	melanoma	VV given i.v. twice, at 3 week intervals		protection from challenge and vitiligo	[Overwijk et al., 1999]

i.m., intramuscular ; i.v., intravenous ; i.p., intraperitoneal